ConcertAI, an oncology-focused real-world data and SaaS startup, has scored $150 million in Series C funding at a $1.9 billion valuation from Sixth Street.
Why it matters: An enormous amount of spend goes towards cancer care, and real-world data and artificial intelligence can ultimately help improve advances in clinical and outcomes research.
